THE Therapeutic Goods Administration has announced that Alectinib (Alecensa) is the first medicine to be registered on the Australian Register of Therapeutic Goods via the new Priority Review Pathway which became effective on 01 Jul 2017.
The medicine was also the first to be granted a priority review determination by the TGA.
The approved application extends the drug's previously registered indications to include the treatment of patients with anaplastic lymphoma kinase (ALK)-positive, locally advanced or metastatic non-small-cell lung cancer.
The above article was sent to subscribers in Pharmacy Daily's issue from 07 Feb 18
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 07 Feb 18
